The Experts below are selected from a list of 1629 Experts worldwide ranked by ideXlab platform
Xiangdong Zhou - One of the best experts on this subject based on the ideXlab platform.
-
Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Apoptosis : an international journal on programmed cell death, 2017Co-Authors: Haijing Wang, Zaixing Yang, Xiao-tian Dai, Yong-feng Chen, Heping Yang, Xiangdong ZhouAbstract:Curcumin, a dietary supplement or herbal medicine from Curcuma longa, has shown antitumor activity in different cancer cell lines and clinical trials. CA916798, a novel protein, is overexpressed in multidrug-resistant tumor cells. This study aimed to assess the effects of curcumin on regulating chemosensitivity in cisplatin-resistant non-small cell lung cancer (NSCLC) cells in vitro and to explore the underlying molecular mechanisms. Human cisplatin-sensitive A549 and cisplatin-resistant A549/CDDP lung adenocarcinoma cells were treated with curcumin to assess cell viability and gene modulations using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. CA916798 shRNA and point mutations were used to assess the CA916798 functions and phosphorylation sites. Bisdemethoxycurcumin sensitized cisplatin-resistant lung cancer cells to various chemotherapeutic agents, including cisplatin. Bisdemethoxycurcumin reduced the levels of CA916798 mRNA and protein in A549 and A549/CDDP cells, while it also suppressed phosphatidylinositol-3-kinase (PI3K)/AKT signaling. CA916798, as a downstream gene, interacted with AKT after Bisdemethoxycurcumin treatment in A549 and A549/CDDP cells. Moreover, A549/CDDP cells expressing the point-mutated CA916798-S20D protein were more resistant to cisplatin and Bisdemethoxycurcumin, whereas tumor cells expressing CA916798-S20A, CA916798-S31A, CA916798-S60A, CA916798-S93A, or CA916798-T97A (different sites of amino acid phosphorylation) showed similar sensitivity or resistance to cisplatin and Bisdemethoxycurcumin, compared with the control cells. Bisdemethoxycurcumin is able to sensitize cisplatin-resistant NSCLC cells to chemotherapeutic agents by inhibition of CA916798 and PI3K/AKT activities. Moreover, phosphorylation of CA916798 at the S20 residue plays a critical role in mediating Bisdemethoxycurcumin antitumor activity.
-
Bisdemethoxycurcumin sensitizes cisplatin resistant lung cancer cells to chemotherapy by inhibition of ca916798 and pi3k akt signaling
Apoptosis, 2017Co-Authors: Haijing Wang, Zaixing Yang, Xiao-tian Dai, Yong-feng Chen, Heping Yang, Xiangdong ZhouAbstract:Curcumin, a dietary supplement or herbal medicine from Curcuma longa, has shown antitumor activity in different cancer cell lines and clinical trials. CA916798, a novel protein, is overexpressed in multidrug-resistant tumor cells. This study aimed to assess the effects of curcumin on regulating chemosensitivity in cisplatin-resistant non-small cell lung cancer (NSCLC) cells in vitro and to explore the underlying molecular mechanisms. Human cisplatin-sensitive A549 and cisplatin-resistant A549/CDDP lung adenocarcinoma cells were treated with curcumin to assess cell viability and gene modulations using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. CA916798 shRNA and point mutations were used to assess the CA916798 functions and phosphorylation sites. Bisdemethoxycurcumin sensitized cisplatin-resistant lung cancer cells to various chemotherapeutic agents, including cisplatin. Bisdemethoxycurcumin reduced the levels of CA916798 mRNA and protein in A549 and A549/CDDP cells, while it also suppressed phosphatidylinositol-3-kinase (PI3K)/AKT signaling. CA916798, as a downstream gene, interacted with AKT after Bisdemethoxycurcumin treatment in A549 and A549/CDDP cells. Moreover, A549/CDDP cells expressing the point-mutated CA916798-S20D protein were more resistant to cisplatin and Bisdemethoxycurcumin, whereas tumor cells expressing CA916798-S20A, CA916798-S31A, CA916798-S60A, CA916798-S93A, or CA916798-T97A (different sites of amino acid phosphorylation) showed similar sensitivity or resistance to cisplatin and Bisdemethoxycurcumin, compared with the control cells. Bisdemethoxycurcumin is able to sensitize cisplatin-resistant NSCLC cells to chemotherapeutic agents by inhibition of CA916798 and PI3K/AKT activities. Moreover, phosphorylation of CA916798 at the S20 residue plays a critical role in mediating Bisdemethoxycurcumin antitumor activity.
Paul J. Dyson - One of the best experts on this subject based on the ideXlab platform.
-
novel osmium ii cymene complexes containing curcumin and Bisdemethoxycurcumin ligands
Inorganic chemistry frontiers, 2019Co-Authors: Riccardo Pettinari, Fabio Marchetti, Claudio Pettinari, Corrado Di Nicola, Massimiliano Cuccioloni, Laura Bonfili, Anna Maria Eleuteri, Bruno Therrien, Lucinda K Batchelor, Paul J. DysonAbstract:The first examples of (arene)Os(II) curcuminoid derivatives have been prepared and characterized. The neutral complexes [(p-cym)Os(curc)Cl] (1) and [(p-cym)Os(bdcurc)Cl] (2), together with the cationic derivatives [(p-cym)Os(curc)(PTA)][SO3CF3] (3) and [(p-cym)Os(bdcurc)(PTA)][SO3CF3] (4) (PTA = 1,3,5-triaza-7-phosphaadamantane) were characterized by NMR spectroscopy and ESI mass spectrometry, and the crystal structure of 1 was determined by X-ray diffraction analysis. The cytotoxicity of the complexes was evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against non-tumorous Human Embryonic Kidney cells (HEK293). Binding of the complexes to potential pharmacological targets and serum carriers was also explored.
-
Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity
Organometallics, 2014Co-Authors: Riccardo Pettinari, Fabio Marchetti, Francesca Condello, Claudio Pettinari, Giulio Lupidi, Rosario Scopelliti, Suman Mukhopadhyay, Tina Riedel, Paul J. DysonAbstract:A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = Bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)][SO3CF3] have been determined by single-crystal X-ray diffraction. The antitumor activity of the complexes has been evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based ligands, i.e. curcumin vs Bisdemethoxycurcumin, is not straightforward. In contrast, the PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported compounds.
-
ruthenium ii arene rapta type complexes containing curcumin and Bisdemethoxycurcumin display potent and selective anticancer activity
Organometallics, 2014Co-Authors: Riccardo Pettinari, Fabio Marchetti, Francesca Condello, Claudio Pettinari, Giulio Lupidi, Rosario Scopelliti, Suman Mukhopadhyay, Tina Riedel, Paul J. DysonAbstract:A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = Bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)][SO3CF3] have been determined by single-crystal X-ray diffraction. The antitumor activity of the complexes has been evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based ligands, i.e. curcumin vs Bisdemethoxycurcumin, is not straightforward. In contrast, the PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported compounds.
Haijing Wang - One of the best experts on this subject based on the ideXlab platform.
-
Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Apoptosis : an international journal on programmed cell death, 2017Co-Authors: Haijing Wang, Zaixing Yang, Xiao-tian Dai, Yong-feng Chen, Heping Yang, Xiangdong ZhouAbstract:Curcumin, a dietary supplement or herbal medicine from Curcuma longa, has shown antitumor activity in different cancer cell lines and clinical trials. CA916798, a novel protein, is overexpressed in multidrug-resistant tumor cells. This study aimed to assess the effects of curcumin on regulating chemosensitivity in cisplatin-resistant non-small cell lung cancer (NSCLC) cells in vitro and to explore the underlying molecular mechanisms. Human cisplatin-sensitive A549 and cisplatin-resistant A549/CDDP lung adenocarcinoma cells were treated with curcumin to assess cell viability and gene modulations using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. CA916798 shRNA and point mutations were used to assess the CA916798 functions and phosphorylation sites. Bisdemethoxycurcumin sensitized cisplatin-resistant lung cancer cells to various chemotherapeutic agents, including cisplatin. Bisdemethoxycurcumin reduced the levels of CA916798 mRNA and protein in A549 and A549/CDDP cells, while it also suppressed phosphatidylinositol-3-kinase (PI3K)/AKT signaling. CA916798, as a downstream gene, interacted with AKT after Bisdemethoxycurcumin treatment in A549 and A549/CDDP cells. Moreover, A549/CDDP cells expressing the point-mutated CA916798-S20D protein were more resistant to cisplatin and Bisdemethoxycurcumin, whereas tumor cells expressing CA916798-S20A, CA916798-S31A, CA916798-S60A, CA916798-S93A, or CA916798-T97A (different sites of amino acid phosphorylation) showed similar sensitivity or resistance to cisplatin and Bisdemethoxycurcumin, compared with the control cells. Bisdemethoxycurcumin is able to sensitize cisplatin-resistant NSCLC cells to chemotherapeutic agents by inhibition of CA916798 and PI3K/AKT activities. Moreover, phosphorylation of CA916798 at the S20 residue plays a critical role in mediating Bisdemethoxycurcumin antitumor activity.
-
Bisdemethoxycurcumin sensitizes cisplatin resistant lung cancer cells to chemotherapy by inhibition of ca916798 and pi3k akt signaling
Apoptosis, 2017Co-Authors: Haijing Wang, Zaixing Yang, Xiao-tian Dai, Yong-feng Chen, Heping Yang, Xiangdong ZhouAbstract:Curcumin, a dietary supplement or herbal medicine from Curcuma longa, has shown antitumor activity in different cancer cell lines and clinical trials. CA916798, a novel protein, is overexpressed in multidrug-resistant tumor cells. This study aimed to assess the effects of curcumin on regulating chemosensitivity in cisplatin-resistant non-small cell lung cancer (NSCLC) cells in vitro and to explore the underlying molecular mechanisms. Human cisplatin-sensitive A549 and cisplatin-resistant A549/CDDP lung adenocarcinoma cells were treated with curcumin to assess cell viability and gene modulations using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. CA916798 shRNA and point mutations were used to assess the CA916798 functions and phosphorylation sites. Bisdemethoxycurcumin sensitized cisplatin-resistant lung cancer cells to various chemotherapeutic agents, including cisplatin. Bisdemethoxycurcumin reduced the levels of CA916798 mRNA and protein in A549 and A549/CDDP cells, while it also suppressed phosphatidylinositol-3-kinase (PI3K)/AKT signaling. CA916798, as a downstream gene, interacted with AKT after Bisdemethoxycurcumin treatment in A549 and A549/CDDP cells. Moreover, A549/CDDP cells expressing the point-mutated CA916798-S20D protein were more resistant to cisplatin and Bisdemethoxycurcumin, whereas tumor cells expressing CA916798-S20A, CA916798-S31A, CA916798-S60A, CA916798-S93A, or CA916798-T97A (different sites of amino acid phosphorylation) showed similar sensitivity or resistance to cisplatin and Bisdemethoxycurcumin, compared with the control cells. Bisdemethoxycurcumin is able to sensitize cisplatin-resistant NSCLC cells to chemotherapeutic agents by inhibition of CA916798 and PI3K/AKT activities. Moreover, phosphorylation of CA916798 at the S20 residue plays a critical role in mediating Bisdemethoxycurcumin antitumor activity.
-
Hypomethylation effects of curcumin, demethoxycurcumin and Bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines
Molecular medicine reports, 2011Co-Authors: Y.-l. Liu, L. Gong, C.-l. Tang, Heping Yang, Haijing WangAbstract:The tumor suppressor gene Wnt inhibitory factor-1 (WIF-1) has been found to be promoter hypermethylated and silenced in lung cancer cell lines and tissues. Curcuminoids are major active components of the spice turmeric, and have recently been reported to be potential hypomethylation agents. In the present study, the hypomethylation effects of three major curcuminoids, curcumin, demethoxycurcumin and Bisdemethoxycurcumin, were compared in vitro using ELISA, and their demethylation potential was confirmed by methylation-specific PCR. It was found that Bisdemethoxycurcumin possesses the strongest demethylation function in vitro compared to the other two curcuminoids, exerting its effect at a minimal demethylation concentration of 0.5-1 µM. The WIF-1 promoter region was demethylated after treatment with 20 µM demethoxycurcumin and Bisdemethoxycurcumin, but failed to respond to 20 µM curcumin. In the A549 cell line, RT-PCR and Western blotting were used to confirm that WIF-1 expression was restored after curcuminoid-induced promoter hypermethylation. Since the results regarding the demethylation potential of the three major curcuminoids to restore WIF-1 expression indicated that Bisdemethoxycurcumin has the strongest hypomethylation effect, this curcuminoid may have therapeutic use in the restoration of WIF-1 expression in NSCLC.
Riccardo Pettinari - One of the best experts on this subject based on the ideXlab platform.
-
novel osmium ii cymene complexes containing curcumin and Bisdemethoxycurcumin ligands
Inorganic chemistry frontiers, 2019Co-Authors: Riccardo Pettinari, Fabio Marchetti, Claudio Pettinari, Corrado Di Nicola, Massimiliano Cuccioloni, Laura Bonfili, Anna Maria Eleuteri, Bruno Therrien, Lucinda K Batchelor, Paul J. DysonAbstract:The first examples of (arene)Os(II) curcuminoid derivatives have been prepared and characterized. The neutral complexes [(p-cym)Os(curc)Cl] (1) and [(p-cym)Os(bdcurc)Cl] (2), together with the cationic derivatives [(p-cym)Os(curc)(PTA)][SO3CF3] (3) and [(p-cym)Os(bdcurc)(PTA)][SO3CF3] (4) (PTA = 1,3,5-triaza-7-phosphaadamantane) were characterized by NMR spectroscopy and ESI mass spectrometry, and the crystal structure of 1 was determined by X-ray diffraction analysis. The cytotoxicity of the complexes was evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against non-tumorous Human Embryonic Kidney cells (HEK293). Binding of the complexes to potential pharmacological targets and serum carriers was also explored.
-
Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity
Organometallics, 2014Co-Authors: Riccardo Pettinari, Fabio Marchetti, Francesca Condello, Claudio Pettinari, Giulio Lupidi, Rosario Scopelliti, Suman Mukhopadhyay, Tina Riedel, Paul J. DysonAbstract:A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = Bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)][SO3CF3] have been determined by single-crystal X-ray diffraction. The antitumor activity of the complexes has been evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based ligands, i.e. curcumin vs Bisdemethoxycurcumin, is not straightforward. In contrast, the PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported compounds.
-
ruthenium ii arene rapta type complexes containing curcumin and Bisdemethoxycurcumin display potent and selective anticancer activity
Organometallics, 2014Co-Authors: Riccardo Pettinari, Fabio Marchetti, Francesca Condello, Claudio Pettinari, Giulio Lupidi, Rosario Scopelliti, Suman Mukhopadhyay, Tina Riedel, Paul J. DysonAbstract:A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = Bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully characterized. The solid-state structures of [Ru(cym)(curc)(PTA)][SO3CF3], [Ru(hmb)(curc)(PTA)][SO3CF3], and [Ru(hmb)(bdcurc)(PTA)][SO3CF3] have been determined by single-crystal X-ray diffraction. The antitumor activity of the complexes has been evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. The correlation of the cytotoxicity upon switching the curcumin-based ligands, i.e. curcumin vs Bisdemethoxycurcumin, is not straightforward. In contrast, the PTA ligand greatly enhances the activity and selectivity of ruthenium compounds in comparison to previously reported compounds.
Soyoung Park - One of the best experts on this subject based on the ideXlab platform.
-
curcuminoids from curcuma longa l zingiberaceae that protect pc12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βa 1 42 insult
Neuroscience Letters, 2001Co-Authors: Soyoung ParkAbstract:β-Amyloid (βA) induced oxidative stress is a well-established pathway of neuronal cell death in Alzheimer's disease. From turmeric, Curcuma longa L. (Zingiberaceae), three curcuminoids, curcumin, demethoxycurcumin, and Bisdemethoxycurcumin, were found to protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial (HUVEC) cells from βA(1–42) insult, as measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reduction assay. ED50 values of curcumin, demethoxycurcumin, and Bisdemethoxycurcumin toward PC12 and HUVEC cells were 7.1±0.3, 4.7±0.1, 3.5±0.2 μg/ml and 6.8±0.4, 4.2±0.3, and 3.0±0.3 μg/ml, respectively. These compounds were better antioxidants than α-tocopherol as determined by DPPH radical trapping experiment. α-Tocopherol did not protect the cells from βA(1–42) insult even at>50 μg/ml concentration. The results suggest that these compounds may be protecting the cells from βA(1–42) insult through antioxidant pathway.
-
curcuminoids from curcuma longa l zingiberaceae that protect pc12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βa 1 42 insult
Neuroscience Letters, 2001Co-Authors: Darrick S H L Kim, Soyoung Park, Jinyung KimAbstract:beta-Amyloid (betaA) induced oxidative stress is a well-established pathway of neuronal cell death in Alzheimer's disease. From turmeric, Curcuma longa L. (Zingiberaceae), three curcuminoids, curcumin, demethoxycurcumin, and Bisdemethoxycurcumin, were found to protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial (HUVEC) cells from betaA(1-42) insult, as measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reduction assay. ED(50) values of curcumin, demethoxycurcumin, and Bisdemethoxycurcumin toward PC12 and HUVEC cells were 7.1+/-0.3, 4.7+/-0.1, 3.5+/-0.2 microg/ml and 6.8+/-0.4, 4.2+/-0.3, and 3.0+/-0.3 microg/ml, respectively. These compounds were better antioxidants than alpha-tocopherol as determined by DPPH radical trapping experiment. alpha-Tocopherol did not protect the cells from betaA(1-42) insult even at>50 microg/ml concentration. The results suggest that these compounds may be protecting the cells from betaA(1-42) insult through antioxidant pathway.